Literature DB >> 21674556

Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.

Romina Lomonaco1, Carolina Ortiz-Lopez, Beverly Orsak, Joan Finch, Amy Webb, Fernando Bril, Christopher Louden, Fermin Tio, Kenneth Cusi.   

Abstract

UNLABELLED: The role of ethnicity in determining disease severity in nonalcoholic steatohepatitis (NASH) remains unclear. We recruited 152 patients with biopsy-proven NASH, 63% of whom were Hispanic and 37% of whom were Caucasian. Both groups were well matched for age, sex, and total body fat. We measured: (1) liver fat by magnetic resonance imaging and spectroscopy; (2) fasting plasma glucose, fasting plasma insulin (FPI), and free fatty acid (FFA) levels; (3) total body fat by dual energy x-ray absorptiometry (DXA); (4) liver and muscle insulin sensitivity (insulin clamp with 3-[(3)H] glucose); (5) insulin resistance at the level of the liver (fasting endogenous glucose production derived from 3-[(3)H] glucose infusion × FPI) and adipose tissue (fasting FFA × FPI). Liver fat was slightly, but not significantly, higher in Hispanic vs. Caucasian patients (27 ± 2% vs. 24 ± 2%, p = 0.16). However, this trend did not translate into worse liver steatosis, necroinflammation or fibrosis. Patients with NASH had severe hepatic, adipose tissue and muscle insulin resistance versus healthy subjects without NASH nonalcoholic fatty liver disease, but there were no differences between both ethnic groups on these parameters. However, Hispanics versus Caucasians with type 2 diabetes mellitus (T2DM) had a trend for worse hepatic/adipose tissue insulin resistance and fibrosis.
CONCLUSION: When Hispanic and Caucasian patients with NASH are well matched for clinical parameters, particularly for adiposity, slightly higher liver fat content is not associated with worse hepatic insulin resistance or more severe NASH on histology. Hispanic ethnicity does not appear to be a major determinant of disease severity in NASH, although those with diabetes may be at greater risk of fibrosis. Given the higher risk of T2DM in Hispanics, long-term studies are needed to define their risk of disease progression.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21674556     DOI: 10.1002/hep.24483

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  Ethnic differences in the link between insulin resistance and elevated ALT.

Authors:  Mark D Deboer; R Constance Wiener; Barrett H Barnes; Matthew J Gurka
Journal:  Pediatrics       Date:  2013-08-12       Impact factor: 7.124

Review 2.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

3.  Ethnicity and nonalcoholic fatty liver disease.

Authors:  Kiran Bambha; Patricia Belt; Maria Abraham; Laura A Wilson; Mark Pabst; Linda Ferrell; Aynur Unalp-Arida; Nathan Bass
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

Review 4.  Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.

Authors:  Jeremy P Middleton; R Constance Wiener; Barrett H Barnes; Matthew J Gurka; Mark D DeBoer
Journal:  Clin Pediatr (Phila)       Date:  2014-01-28       Impact factor: 1.168

Review 5.  Gender and racial differences in nonalcoholic fatty liver disease.

Authors:  Jen-Jung Pan; Michael B Fallon
Journal:  World J Hepatol       Date:  2014-05-27

6.  An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Romina Lomonaco; Janet Chen; Kenneth Cusi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 7.  NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Authors:  Subada Soti; Kathleen E Corey; Jordan E Lake; Kristine M Erlandson
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

8.  Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease.

Authors:  Nishanth E Sunny; Srilaxmi Kalavalapalli; Fernando Bril; Timothy J Garrett; Manisha Nautiyal; Justin T Mathew; Caroline M Williams; Kenneth Cusi
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-06-09       Impact factor: 4.310

Review 9.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

10.  Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage.

Authors:  Eric R Kallwitz; Martha L Daviglus; Matthew A Allison; Kristen T Emory; Lihui Zhao; Mark H Kuniholm; Jinsong Chen; Natalia Gouskova; Amber Pirzada; Gregory A Talavera; Marston E Youngblood; Scott J Cotler
Journal:  Clin Gastroenterol Hepatol       Date:  2014-09-15       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.